Assura PLC
LSE:AGR

Watchlist Manager
Assura PLC Logo
Assura PLC
LSE:AGR
Watchlist
Price: 47.48 GBX 0.38%
Market Cap: £1.5B

EV/EBITDA

19.4
Current
0%
More Expensive
vs 3-y average of 19.4

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
19.4
=
Enterprise Value
GBX3B
/
EBITDA
£152.4m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
19.4
=
Enterprise Value
GBX3B
/
EBITDA
£152.4m

Valuation Scenarios

Assura PLC is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (19.4), the stock would be worth GBX47.43 (0% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-100%
Maximum Upside
+1%
Average Downside
50%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 19.4 GBX47.48
0%
3-Year Average 19.4 GBX47.43
0%
5-Year Average 19.7 GBX48.13
+1%
Industry Average 0.1 GBX0.19
-100%
Country Average 0 GBX0.05
-100%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
GBX3B
/
Apr 2025
£152.4m
=
19.4
Current
GBX3B
/
Mar 2026
£149.3m
=
19.8
Forward
GBX3B
/
Mar 2027
£154m
=
19.2
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
UK
Assura PLC
LSE:AGR
1.5B GBP 19.4 9.3
US
Welltower Inc
NYSE:WELL
145B USD 64.8 154.8
US
Ventas Inc
NYSE:VTR
39.4B USD 21.4 156.7
US
Omega Healthcare Investors Inc
NYSE:OHI
13.7B USD 16.7 23.9
US
Physicians Realty Trust
NYSE:DOC
11.4B USD 12.8 162.2
US
Healthpeak Properties Inc
F:HC5
9.7B EUR 12.7 161.6
US
CareTrust REIT Inc
NYSE:CTRE
8.5B USD 22.1 26.4
BE
Aedifica NV
XBRU:AED
6.1B EUR 25.4 24.9
US
Healthcare Realty Trust Inc
NYSE:HR
6.5B USD 15.9 -26.3
US
Healthcare Trust Of America Inc
F:HT01
5.3B EUR 20.1 66.4
US
Sabra Health Care REIT Inc
NASDAQ:SBRA
5B USD 16.7 32.1

Market Distribution

Higher than 96% of companies in United Kingdom
Percentile
96th
Based on 1 967 companies
96th percentile
19.4
Low
0 — 0
Typical Range
0 — 0
High
0 —
Distribution Statistics
United Kingdom
Min 0
30th Percentile 0
Median 0
70th Percentile 0
Max 743.2

Assura PLC
Glance View

In the ever-evolving landscape of healthcare infrastructure, Assura PLC has carved out a niche, specializing in the development and management of primary care properties across the UK. With a keen understanding of the public and private sector disparities within the healthcare industry, Assura operates essentially as a real estate investment trust (REIT), focusing on assets that provide essential healthcare services. Their business model is grounded in creating and maintaining robust and modern facilities that serve as the backbone for general practitioners, dentists, and other community health services. By partnering with the National Health Service (NHS), Assura ensures that these facilities not only meet current standards but also anticipate future healthcare needs, ensuring long-term sustainability and growth opportunities. Revenue generation for Assura PLC primarily revolves around rental income derived from the leasing of these healthcare properties. With a portfolio spanning several hundred properties, Assura capitalizes on long-term leases, often with inflation-linked rent reviews, providing them with a stable and predictable income. This strategy affords them the advantage of minimizing vacancy risks, given their collaboration with the NHS and the ongoing demand for modern healthcare facilities. By focusing on niche real estate like medical centers and community hospitals, Assura aligns its financial objectives with the critical needs of public health infrastructure, positioning itself as an essential player in ensuring the organic expansion of primary healthcare services throughout the UK.

AGR Intrinsic Value
29.79 GBX
Overvaluation 37%
Intrinsic Value
Price GBX47.48
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett